CLAIMS

1. A compound of the formula (I):



(I)

wherein:

V is selected from CH_2 and NH, and W is selected from NR^1 and NR^2; or V is selected from NR^1 and NR^2, and W is selected from CH_2 and NH;

X is selected from CH_2 and CHOH in the R or S-configuration;

Y is selected from hydrogen, halogen and hydroxy, except where V is selected from NH, NR^1 and NR^2 then Y is hydrogen;

Z is selected from hydrogen, halogen, hydroxy, SQ, OQ and Q, where Q is an optionally substituted alkyl, aralkyl or aryl group;

R^1 is a radical of the formula (II)



(II)

R^2 is a radical of the formula (III)



(III)

A is selected from N, CH and CR, where R is selected from halogen, optionally substituted alkyl, aralkyl or aryl, OH, NH_2, NHR^3, NR^3R^4 and SR^5, where R^3, R^4 and R^5 are each optionally substituted alkyl, aralkyl or aryl groups;

B is selected from OH, NH_2, NHR^6, SH, hydrogen and halogen, where R^6 is an optionally substituted alkyl, aralkyl or aryl group;

D is selected from OH, NH_2, NHR^7, hydrogen, halogen and SCH_3, where R^7 is an optionally substituted alkyl, aralkyl or aryl group;

E is selected from N and CH;

G is selected from CH_2 and NH, or G is absent, provided that where W is NR^1 or NR^2 and G is NH then V is CH_2, and provided that where V is NR^1 or NR^2 and G is NH then W is CH_2;

or a tautomer thereof, or a pharmaceutically acceptable salt thereof, or an ester thereof, or a prodrug thereof.

2. A compound as claimed in claim 1 where Z is selected from hydrogen, halogen, hydroxy, SQ and OQ.

3. A compound as claimed in claim 1 or claim 2 where V is CH_2.

4. A compound as claimed in any one of claims 1 to 3, where X is CH_2.

5. A compound as claimed in any one of claims 1 to 4, where G is CH_2.

6. A compound as claimed in any one of claims 1 to 5 where Z is OH.

7. A compound as claimed in any one of claims 1 to 5 where Z is SQ.

8. A compound as claimed in any one of claims 1, 3, 4 or 5 where Z is Q.

9. A compound as claimed in any one of claims 1 to 8, where W is NR^1.

10. A compound as claimed in any one of claims 1 to 8, where W is NR^2.

11. A compound as claimed in any one of claims 1 to 8, where W is selected from NH, NR^1 or NR^2 and X is CH_2.

12. A compound as claimed in any one of claims 1, 2, 3, 4, 5, 6 or 9 where V, X and G are all CH_2, Z is OH and W is NR^1.

13. A compound as claimed in any one of claims 1, 2, 3, 4, 5, 7 or 9 where V, X and G are all CH_2, Z is SQ and W is NR^1.

14. A compound as claimed in any one of claims 1 to 13 where Y is hydrogen.

15. A compound as claimed in any one of claims 1 to 13 where Y is hydroxy.

16. A compound as claimed in any one of claims 1 to 15 where B is hydroxy.

17. A compound as claimed in any one of claims 1 to 15 where B is NH_2.

18. A compound as claimed in any one of claims 1 to 17 where A is CH.

19. A compound as claimed in any one of claims 1 to 17 where A is N.

20. A compound as claimed in any one of claims 1 to 19 where D is H

21. A compound as claimed in any one of claims 1 to 19 where D is NH_2.

22. A compound as claimed in any one of claims 1 to 21 where E is N.

23. A compound as claimed in claim 1, which is:
(3R,4R)-1-[(9-deazahypoxanthin-9-yl)methyl]-3-hydroxy-4-(hydroxymethyl)pyrrolidine;
(3R,4R)-1-[(9-Deazaadenin-9-yl)methyl]-3-hydroxy-4-(hydroxylmethyl)pyrrolidine;
(3R,4R)-1-[(8-aza-9-deazahypoxanthin-9-yl)methyl]-3-hydroxy-4-(hydroxymethyl)pyrrolidine;
(3R,4R)-1-[(8-aza-9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(hydroxymethyl)pyrrolidine;
(3R,4S)-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(2-phenylethyl)pyrrolidine;
(3S,4R)-1-[(9-deazahypoxanthin-9-yl)methyl]-3,4-dihydroxy-4-methylthiomethylpyrrolidine;
(3R,4S)-1-[(9-deazahypoxanthin-9-yl)methyl]-3-hydroxy-4-(methylthiomethyl)pyrrolidine;
N-(9-Deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol;
N-(9-deazahypoxanthin-9-yl)methyl-1,4-dideoxy-1,4-imino-D-ribitol;
(3R,4R)-3-hydroxy-4-hydroxymethyl-1-(hypoxanthin-9-yl)pyrrolidine;
(3R,4S)-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(methylthiomethyl)pyrrolidine;
(3R,4S)-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(benzylthiomethyl)pyrrolidine;
(3R,4S)-1-[(8-aza-9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(benzylthiomethyl)pyrrolidine;

(3R,4R)-1-[(9-deazaguanin-9-yl)methyl]-3-hydroxy-4-(hydroxymethyl)pyrrolidine;
(3R,4S)-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(4-chlorophenylthiomethyl)pyrrolidine;
(3R,4R)-1-[(6-chloro-9-deazapurin-9-yl)methyl]-3-hydroxy-4-(hydroxymethyl)pyrrolidine;
(3R,4R)-1-[(6-azido-9-deazapurin-9-yl)methyl]-3-hydroxy-4-(hydroxymethyl)pyrrolidine; or
(3R,4R)-1-[(9-deazaadenin-9-yl)methyl]-3-acetoxy-4-(acetoxymethyl)pyrrolidine;
or a pharmaceutically acceptable salt thereof, or an ester thereof, or a prodrug thereof.

24. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound as claimed in any one of claims 1 to 23.

25. A method of treating a disease or condition in which it is desirable to inhibit purine phosphoribosyltransferase, purine nucleoside phosphorylase, 5'-methylthioadenosine phosphorylase, 5'-methylthioadenosine nucleosidase and/or nucleoside hydrolase comprising administering a pharmaceutically effective amount of a compound as claimed in any one of claims 1 to 23 to a patient requiring treatment.

26. The method of claim 25, where the disease or condition is cancer, bacterial infection, protozoal infection or a T-cell mediated disease.

27. The method of claim 26, where the T-cell mediated disease is psoriasis, arthritis or transplant rejection.

28. The use of a compound as claimed in any one of claims 1 to 23 in the manufacture of a medicament for treating a disease or condition in which it is desirable to inhibit purine phosphoribosyltransferase, purine nucleoside phosphorylase, 5'-methylthioadenosine phosphorylase, 5'-methylthioadenosine nucleosidase and/or nucleoside hydrolase.